Conshohocken’s Madrigal Pharmaceuticals is making a major move that could reshape the future of liver disease treatment, writes John George for The Philadelphia Business Journal.
The biotech firm announced a global licensing agreement potentially worth more than $4 billion. The deal will expand its pipeline of therapies targeting metabolic dysfunction-associated steatohepatitis, or MASH.
Under the deal, Madrigal will pay $60 million upfront to China-based Suzhou Ribo Life Science, with additional milestone payments tied to development and commercial goals.
Madrigal is best known locally for Rezdiffra, the first FDA-approved treatment for MASH. The drug has quickly become a commercial success, generating more than $637 million in sales through the first three quarters of 2025 after launching in April 2024.
The newly licensed programs focus on small interference RNA therapies aimed at genetic drivers of the disease. Company leaders say combining these gene-targeting treatments with Rezdiffra could create a new generation of precision therapies for patients facing serious liver complications, including cirrhosis and transplant risk.
For a company that began 2025 with a single product, the Conshohocken company now boasts a pipeline of more than 10 MASH-focused programs.
To learn more about the deal and its implications for the industry, visit The Philadelphia Business Journal.
